Provided by Tiger Trade Technology Pte. Ltd.

Harris Concept

3,704.91
+58.251.60%
Number of Gainers:17
Number of Losers:5
Number of Flat:- -
PE:- -
High:3,713.30
Open:3,647.14
Low:3,647.14
Close:3,646.66
Volume:193.22M
Turnover:18.08B
Market Cap:4.47T
Float Cap:3.82T

Loading ...

Here's Another Way Rising Bond Yields Could Take a Bite Out of Americans' Wallets

Dow Jones
·
Sep 03

Update: Amazon Teamsters Launch One-Day Strike at California Warehouse

MT Newswires Live
·
Sep 03

Most Active Stocks: Meta Tops List with 27% Upside, Strong Buy Rating

TIPRANKS
·
Sep 03

Cboe data shows mixed options sentiment in Amazon with shareslittle changed

TIPRANKS
·
Sep 03

Coinbase launches 10x crypto futures in Canada

cryptonews
·
Sep 03

Teva Upgraded to Buy on Strengthening Autoimmune Pipeline and Validating Celiac Disease Data

TIPRANKS
·
Sep 03

Target - Opens Eight New Stores in Six States in Fall 2026

THOMSON REUTERS
·
Sep 02

Amazon Teamsters Launch One-Day Strike at Tech Giant's Largest US Warehouse

MT Newswires Live
·
Sep 02

Teamsters - Amazon Teamsters Launch One-Day Ulp Strike at Djt6 Riverside Facility

THOMSON REUTERS
·
Sep 02

Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live
·
Sep 02

Sam's Club Facility Breaks Ground in Nanchang High-Tech Zone

Deep News
·
Sep 02

Strategy - Carahsoft to Offer Strategy Mosaic Platform to Public Sector

THOMSON REUTERS
·
Sep 02

Strategy and Carahsoft Partner to Streamline AI-Powered Governed Mission Data for Government Agencies

THOMSON REUTERS
·
Sep 02

Target Files 10-Q for Quarter Ended Aug. 1, 2026

Reuters
·
Sep 02

US-Listed Shares of Teva Pharmaceutical up 3.5% Premarket After Co's Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
Sep 02

Teva's Stock Jumps over 3% as Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

Reuters
·
Sep 02

Strategy Initiated at Buy by Alliance Global Partners

Dow Jones
·
Sep 02

Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease

MT Newswires Live
·
Sep 02

Teva: Tev '408 was Well-Tolerated with no Safety Signals Observed to Date

THOMSON REUTERS
·
Sep 02

Teva - Tev ‘408 Demonstrates Statistically Significant Prevention of Gluten-Induced Damage in Phase 2a Study

THOMSON REUTERS
·
Sep 02